MorphoSys planning BLA for DLBCL candidate on Phase II data

MorphoSys AG (Xetra:MOR; Pink:MPSYY) said it discussed with FDA the possibility of expedited regulatory submission and approval for its MOR208 (MOR00208) to treat relapsed or refractory diffuse large B cell

Read the full 308 word article

User Sign In